The Table of Contents is as follows:

ABOUT THE OECD
FOREWORD
PREAMBLE
GENERAL INTRODUCTION
A. General Considerations
1. Subject of document; species included and taxonomic considerations
2. Characteristics of the organism which permit identification, and the methods used
2.1. Characterization of the Genus Acinetobacter
2.2. Differentiation of Acinetobacter from Related Taxa.
2.3. The Species of Acinetobacter.
2.4. Biotyping of Strains within Species
3. Biological features
3.1. Growth Requirements
3.2. Main Physiological Attributes.
3.3. Temperature.
3.4. pH and salt.
3.5. Survival.
3.6. Dissemination and adhesion.
3.7. Bioemulsans
4. Simulated systems used to study behaviour of Acinetobacter in clinical and natural environments.
5. History of use (examples of environmental and industrial applications):
5.1. Removal of Phosphates
5.2. Bioremediation of Industrial Pollutants
5.3. Stabilization of oil-water emulsions, biosorption, and bioemulsans.
5.4. Other applications
6. Chromosome and plasmid genetics and genomics
6.1. Whole genome sequencing
6.2. Plasmids.
6.3. Transposons and integrons.
6.4. Plasmid and Chromosome Stability.
7. Capability to horizontally transfer genetic information
7.1. Transformation.
7.2. Transduction.
7.3. Conjugation.
B. Human Health Considerations
8. Diseases caused and mechanism of pathogenicity, including invasiveness and virulence
8.1. General Overview.
8.2. Respiratory Infections.
8.3. Bacteraemia.
8.4. Peritonitis.
8.5. Meningitis.
8.6. Possible link with transmissible spongiform encephalopathies
8.7. Comments on each species.
9. Communicability and means of dissemination of medically-relevant strains in community-acquired
and clinically-acquired infections
10. Infective dose.
11. Host range.
12. Capacity for colonization.
13. Possibility for survival outside of human host.
14. Antibiotic resistance.
14.1. Resistance to antibiotics and other anti-microbials.
14.2. Mechanisms and Genetics of Antibiotic Resistance
14.3. Use in Differentiation and Epidemiology.
14.4. Horizontal dissemination of Antibiotic resistant amongst Acinetobacter in the clinical and nonclinical environment
15. Toxigenicity and pathogenicity.
16. Allergenicity.
17. Availability of appropriate prophylaxis and therapies.
C. Environmental and Agricultural Considerations
18. Natural habitat and geographic distribution, climatic characteristics of original habitats.
18.1. General Overview.
18.2. Comments on Each Species.
19. Non-human pathogenicity
19.1. Plant Pathogenicity.
19.2. Non-Human Animal Pathogenicity.
20. Interactions with and effects on other organisms in the environment.
20.1. Enhancement of plant growth and other effects.
20.2. Antagonism to plant pathogens.
20.3. Cooperative and symbiotic interactions
20.4. Horizontal gene transfer in the environment, on plants, and in animals
21. Ability to form survival structures (e.g. spores, sclerotia).
22. Routes of dissemination in the environment, physical or biological.
23. Containment and decontamination in clinical and non-clinical settings.
24. Detection and monitoring techniques in clinical and non-clinical environments
24.1. General Isolation Media.
24.2. Isolation from Non-Clinical Material.
24.3. Isolation from Clinical Material.
24.4. Detection methods that do not require cultivation
USEFUL REFERENCES (NOT CITED)
REFERENCES CITED
QUESTIONNAIRE TO RETURN TO THE OECD